Sign in
4

Changes in Ownership

ArriVent BioPharma, Inc. Filed Acc 0001104659-26-121410

Chief Operating Officer acquired 40,693 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

LaChapelle Robin · Chief Operating Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2026-10-30 Exercise or conversion : show line 1 in the form +16,265 $3.65 $59,374 152,001 D
2026-10-30 Exercise or conversion : show line 2 in the form +410 $2.28 $935 152,411 D
2026-10-30 Exercise or conversion : show line 3 in the form +4,550 $2.28 $10,381 156,961 D
2026-10-30 Exercise or conversion : show line 4 in the form +1,820 $2.28 $4,152 158,781 D
2026-10-30 Exercise or conversion : show line 5 in the form +17,648 $6.24 $110,055 176,429 D

Table II: Derivative

5 lines
Date Transaction Shares Owned after D/I
2026-10-30 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −410 0 D
2026-10-30 Exercise or conversion : show line 7 in the form Stock Option (right to buy) −4,550 1,820 D
2026-10-30 Exercise or conversion : show line 8 in the form Stock Option (right to buy) −1,820 0 D
2026-10-30 Exercise or conversion : show line 9 in the form Stock Option (right to buy) −16,265 2,600 D
2026-10-30 Exercise or conversion : show line 10 in the form Stock Option (right to buy) −17,648 38,823 D
Loading xslF345X06/tm2628786-1_4seq1.xml…